Alexion Pharmaceuticals Inc (ALXN)

pos +0.18
Today's Range: 119.03 - 122.65 | ALXN Avg Daily Volume: 1,334,300
Last Update: 10/26/16 - 4:00 PM EDT
Volume: 3,834,221
YTD Performance: -36.35%
Open: $121.55
Previous Close: $121.41
52 Week Range: $110.56 - $205.29
Oustanding Shares: 224,247,998
Market Cap: 27,270,799,037
6-Month Chart
TheStreet Ratings Grade for ALXN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 12 11 11 12
Moderate Buy 2 2 2 2
Hold 5 5 4 4
Moderate Sell 0 0 0 0
Strong Sell 1 1 0 0
Mean Rec. 1.77 1.82 1.56 1.53
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 405.37
Price Earnings Comparisons:
ALXN Sector Avg. S&P 500
405.37 296.60 29.60
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-4.75% -29.07% -3.00%
Revenue 16.60 1.30 0.32
Net Income -78.00 -0.40 -0.17
EPS -79.40 -0.50 -0.20
Earnings for ALXN:
Revenue 2.60B
Average Earnings Estimates
Qtr (09/16) Qtr (12/16) FY (12/16) FY (12/17)
Average Estimate $1.04 $1.12 $3.87 $5.15
Number of Analysts 1 1 1 1
High Estimate $1.04 $1.12 $3.87 $5.15
Low Estimate $1.04 $1.12 $3.87 $5.15
Prior Year $0.93 $0.84 $4.55 $3.87
Growth Rate (Year over Year) 11.83% 33.33% -14.95% 33.07%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Jul 11, 2016 | 7:57 AM EDT
ALXN was upgraded from Neutral to Outperform, Credit Suisse said. Valuation call, based on a $165 price target.
Too many turn bearish too quickly just because they can't find any entry points.
Big move for biotechs isn't pleasant.
U.S. indices are up as oil continues its climb past $50 a barrel.
Apr 29, 2016 | 7:18 AM EDT
ALXN was upgraded to Outperform, BMO Capital said. $168 price target. Sell-off after earnings has created a buying opportunity.
Crude prices were also falling following the BOJ's decision to keep its monetary policy unchanged. 
The next potential support levels are the $120 and $100 areas from 2013.

Novice Trade: Illumina Real Money Pro($)

ILMN's three-month at-the-money implied volatility is at about the median level.
Oct 02, 2015 | 7:50 AM EDT
ALXN was upgraded to Overweight, Morgan Stanley said. $211 price target. Orphan drugs should not face pricing concerns and the company ...
Sep 14, 2015 | 8:09 AM EDT
ALXN was downgraded from Overweight to Equal-weight, Barclays said. $205 price target. Expects delays in Strensiq and Kanuma launches.

Columnist Conversations

Raytheon is building on Tuesday's impressive breakout.  The defense name is up over 1.25% ahead of tonigh...
Merck had a nice earnings beat on Tuesday which was accompanied by an earlier than expected FDA approval on Ke...
For years Apple was accused of under promise, over deliver --- UPOD as Jim Cramer likes to call it.  Whil...
Market down across the board, as less than optimistic outlook from Apple (AAPL) dampens investor enthusiasm in...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.